Collaborative Research, Development And License Agreement Sample Contracts

Collaborative Research, Development and License Agreement: Consent and Payment Direction (March 9th, 2017)

As we have discussed, Curis, Inc., a Delaware corporation ("Curis"), is in the process of discussing, under confidentiality agreements, a potential refinancing of the existing debt financing (the "Transaction") of Curis Royalty LLC, a wholly owned subsidiary of Curis (the "Borrower") by HealthCare Royalty Partners III, L.P. (the "Investor"), where the debt would be secured by the Borrower's rights to receive certain payments under that certain Collaborative Research, Development and License Agreement, dated as of June 11, 2003, by and between Curis and Genentech, Inc. ("Genentech"), as amended as of December 10, 2004, April 11, 2005, May 8, 2006 and again as of April 26, 2012 (the "License Agreement"). As noted below, you have previously consented to the assignment of certain payment rights under the License Agreement from Curis to the Borrower. In connection with the Transaction, by this letter agreement ("Letter Agreement"), Curis is seeking Genentech's consent under Section 16.8 o

Collaborative Research, Development and License Agreement (August 6th, 2015)
Amendment to 1999 Collaborative Research, Development and License Agreement (June 5th, 2013)

THIS AMENDMENT TO 1999 COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the Amendment) is entered into as of May 31, 2013 (the Effective Date) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC (FKA ALLERGAN SALES, INC.), a limited liability company organized in the State of California, with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a company incorporated in the State of Delaware, with offices at 2525 Dupont Drive, Irvine, CA 92612 (hereinafter collectively, Allergan).

Collaborative Research, Development and License Agreement (November 6th, 2012)
Sixth Amendment to Collaborative Research, Development and License Agreements (May 10th, 2011)

THIS SIXTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (the Sixth Amendment) is entered into as of March 28, 2011 (the Sixth Amendment Effective Date) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC, a Delaware limited liability company (Allergan) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.

Amendment No. 1 to Collaborative Research, Development and License Agreement (January 14th, 2011)

This AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the Amendment) is entered into as of October 8, 2010 (the Effective Date) by and between ArQule, Inc. and Daiichi Sankyo Co., Ltd. (collectively, the Parties).

Amendment No. 1 to Collaborative Research, Development and License Agreement (November 9th, 2010)

This AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the Amendment) is entered into as of October 8, 2010 (the Effective Date) by and between ArQule, Inc. and Daiichi Sankyo Co., Ltd. (collectively, the Parties).

Fifth Amendment to Collaborative Research, Development and License Agreements (May 10th, 2010)

THIS FIFTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (the Fifth Amendment) is entered into as of March 23, 2010 (the Fifth Amendment Effective Date) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC, a Delaware limited liability company (Allergan) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.

Fourth Amendment to Collaborative Research, Development and License Agreements (August 5th, 2009)

THIS FOURTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (the Fourth Amendment) is entered into as of April 22, 2009 (the Fourth Amendment Effective Date) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC, a Delaware limited liability company (Allergan) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.

COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT Between ARQULE, INC. And DAIICHI SANKYO CO., LTD November 7, 2008 (March 6th, 2009)

This COLLABORATIVE RESEARCH DEVELOPMENT AND LICENSE AGREEMENT (this Agreement) is entered into as of November 7, 2008, by and between ARQULE, Inc., a Delaware corporation with offices at 19 Presidential Way, Woburn, MA 01801-5140 (ARQULE), and Daiichi Sankyo Co., Ltd, a Japanese company organized under the laws of Japan with offices at 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan (DS). Each of DS and ARQULE is sometimes referred to individually herein as a Party and collectively as the Parties.

Third Amendment to Collaborative Research, Development and License Agreements (May 5th, 2008)

THIS THIRD AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (the Third Amendment) is entered into as of March 3, 2008 (the Third Amendment Effective Date) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC, a Delaware limited liability company (Allergan) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.

Second Amendment to Collaborative Research, Development and License Agreement (March 15th, 2006)

THIS SECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the Second Amendment) is entered into as of February 28, 2006 (the Second Amendment Effective Date) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES LLC a Delaware limited liability company, (Allergan), with offices at 2525 Dupont Drive, Irvine, CA 92623, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.

Second Amendment to Collaborative Research, Development and License Agreement Between Curis and Genentech (April 19th, 2005)

This Second Amendment (the Amendment), effective as of April 11, 2005 (the Amendment Date), is made by and between Curis, Inc., a Delaware corporation (Curis), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and Genentech, Inc., a Delaware corporation (Genentech), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to individually as a Party and collectively as the Parties.

First Amendment to Collaborative Research, Development and License Agreement Between Curis and Genentech (March 15th, 2005)

This First Amendment (the Amendment), effective as of December 10, 2004 (the Amendment Date), is made by and between Curis, Inc., a Delaware corporation (Curis), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and Genentech, Inc., a Delaware corporation (Genentech), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to individually as a Party and collectively as the Parties.

Targacept – COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT Between TARGACEPT, INC. And DR. FALK PHARMA GmbH (December 15th, 2004)

This Collaborative Research, Development and License Agreement (this Agreement) is made and entered into as of January 26, 2001, by and between Targacept, Inc., a Delaware corporation having its principal place of business at 950 Reynolds Boulevard, Winston-Salem, North Carolina 27105 (Targacept), and Dr. Falk Pharma GmbH, a corporation organized and existing under the laws of Germany having its place of business at Leinenweberstrasse 5, 79041 Freiburg, Germany (Dr. Falk) (each of Targacept and Dr. Falk, a Party and, collectively, the Parties).

COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT by and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. And ALLERGAN SALES, LLC (May 25th, 2004)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), entered into as of March 27, 2003 (the Effective Date) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively Allergan), both having offices at 2525 Dupont Drive, Irvine, California 92612.

COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT by and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. And ALLERGAN SALES, LLC (May 25th, 2004)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), entered into as of March 27, 2003 (the Effective Date) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively Allergan), both having offices at 2525 Dupont Drive, Irvine, California 92612.

COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT Among ACADIA PHARMACEUTICALS INC., and ALLERGAN, INC. And ALLERGAN PHARMACEUTICALS (IRELAND) LIMITED, INC. And ALLERGAN SALES, INC. (May 25th, 2004)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), entered into as of July 26, 1999 (the Effective Date) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121 and ALLERGAN PHARMACEUTICALS (IRELAND) LIMITED, INC. a Panamanian corporation with offices at Castlebar road Westport, County Mayo, Ireland, ALLERGAN SALES, INC. a California corporation with offices at 2525 Dupont Drive, Irvine, California 92612 and ALLERGAN, INC., a Delaware corporation, with offices at 2525 Dupont Drive, Irvine, California 92612 (hereinafter collectively Allergan),

COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT by and Among ACADIA PHARMACEUTICALS INC., VISION PHARMACEUTICALS L.P. And ALLERGAN, INC. (May 25th, 2004)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the Agreement) is entered into as of September 24, 1997 (the Effective Date) by and between ACADIA PHARMACEUTICALS INC. (previously known as Receptor Technologies, Inc.), a Delaware corporation (ACADIA) with offices at 276 East Allen, Winooski, VT 05404, VISION PHARMACEUTICALS L.P., a Texas limited partnership (Allergan), with offices at 2525 Dupont Drive, Irvine, CA 92623 and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Vision Pharmaceuticals L.P.

Targacept – COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT Between TARGACEPT, INC. And DR. FALK PHARMA GmbH (May 14th, 2004)

This Collaborative Research, Development and License Agreement (this Agreement) is made and entered into as of January 26, 2001, by and between Targacept, Inc., a Delaware corporation having its principal place of business at 950 Reynolds Boulevard, Winston-Salem, North Carolina 27105 (Targacept), and Dr. Falk Pharma GmbH, a corporation organized and existing under the laws of Germany having its place of business at Leinenweberstrasse 5, 79041 Freiburg, Germany (Dr. Falk) (each of Targacept and Dr. Falk, a Party and, collectively, the Parties).

COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT by and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. And ALLERGAN SALES, LLC (February 27th, 2004)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), entered into as of March 27, 2003 (the Effective Date) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (ACADIA), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively Allergan), both having offices at 2525 Dupont Drive, Irvine, California 92612.

Renovis, Inc. – Collaborative Research, Development and License Agreement (February 3rd, 2004)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), entered into as of December 31, 2003 (the Effective Date), by and between RENOVIS, INC., a Delaware corporation (Renovis), with offices at Two Corporate Drive, South San Francisco, CA 94080, and GENENTECH, INC., a Delaware corporation (Genentech), with offices at 1 DNA Way, South San Francisco, California 94080. Renovis and Genentech may each be referred to herein individually as a Party and collectively as the Parties.

Renovis, Inc. – Collaborative Research, Development and License Agreement (January 16th, 2004)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), entered into as of December 31, 2003 (the Effective Date), by and between RENOVIS, INC., a Delaware corporation (Renovis), with offices at Two Corporate Drive, South San Francisco, CA 94080, and GENENTECH, INC., a Delaware corporation (Genentech), with offices at 1 DNA Way, South San Francisco, California 94080. Renovis and Genentech may each be referred to herein individually as a Party and collectively as the Parties.

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT by and Between CURIS, INC. And GENENTECH, INC. (July 10th, 2003)

THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), entered into as of June 11, 2003 (the Effective Date), by and between CURIS, INC., a Delaware corporation (Curis), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and GENENTECH, INC., a Delaware corporation (Genentech), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to herein individually as a Party and collectively as the Parties.